Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity
- PMID: 16730260
- DOI: 10.1016/S0065-2776(06)90001-7
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity
Abstract
Cellular transformation and tumor development result from an accumulation of mutational and epigenetic changes that alter normal cell growth and survival pathways. For the last 100 years, there has been a vigorous debate as to whether the unmanipulated immune system can detect and eliminate such altered host derived cells despite the fact that cancer cells frequently express either abnormal proteins or abnormal levels of normal cellular proteins that function as tumor antigens. In this review, we discuss the current state of this argument and point out some of the recent key experiments demonstrating that immunity not only protects the host from cancer development (i.e., provides a cancer immunosurveillance function) but also can promote tumor growth, sometimes by generating more aggressive tumors. The terminology "cancer immunoediting" has been used to describe this dual host protective and tumor promoting action of immunity, and herein we summarize the ever-increasing experimental and clinical data that support the validity of this concept.
Similar articles
-
Mechanisms of immune evasion by tumors.Adv Immunol. 2006;90:51-81. doi: 10.1016/S0065-2776(06)90002-9. Adv Immunol. 2006. PMID: 16730261 Review.
-
Interferons, immunity and cancer immunoediting.Nat Rev Immunol. 2006 Nov;6(11):836-48. doi: 10.1038/nri1961. Nat Rev Immunol. 2006. PMID: 17063185 Review.
-
Immune cells as anti-cancer therapeutic targets and tools.J Cell Biochem. 2007 Jul 1;101(4):918-26. doi: 10.1002/jcb.21230. J Cell Biochem. 2007. PMID: 17265430 Review.
-
Natural immunity to cancer in humans.Curr Opin Immunol. 2010 Apr;22(2):215-22. doi: 10.1016/j.coi.2010.02.006. Epub 2010 Mar 6. Curr Opin Immunol. 2010. PMID: 20207124 Review.
-
Cancer immunoediting and "spontaneous" tumor regression.Pathol Res Pract. 2010 Jan 15;206(1):1-8. doi: 10.1016/j.prp.2009.10.001. Epub 2009 Nov 27. Pathol Res Pract. 2010. PMID: 19945228 Review.
Cited by
-
Bone-immune cell crosstalk: bone diseases.J Immunol Res. 2015;2015:108451. doi: 10.1155/2015/108451. Epub 2015 Apr 27. J Immunol Res. 2015. PMID: 26000310 Free PMC article. Review.
-
Reactive Oxygen Species and Antitumor Immunity-From Surveillance to Evasion.Cancers (Basel). 2020 Jul 1;12(7):1748. doi: 10.3390/cancers12071748. Cancers (Basel). 2020. PMID: 32630174 Free PMC article. Review.
-
The new deal: a potential role for secreted vesicles in innate immunity and tumor progression.Front Immunol. 2015 Feb 24;6:66. doi: 10.3389/fimmu.2015.00066. eCollection 2015. Front Immunol. 2015. PMID: 25759690 Free PMC article. Review.
-
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells.Cancer Immunol Immunother. 2023 May;72(5):1139-1151. doi: 10.1007/s00262-022-03319-w. Epub 2022 Nov 7. Cancer Immunol Immunother. 2023. PMID: 36342511 Free PMC article.
-
Emerging Trends in Immunotherapy for Cancer.Diseases. 2022 Sep 6;10(3):60. doi: 10.3390/diseases10030060. Diseases. 2022. PMID: 36135216 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources